A Long Term Safety Study With Atrasentan

A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

NCT00257478 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

NCT00286793 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

NCT07005154 ·Status: RECRUITING ·Phase: PHASE2

A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

NCT00286806 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

NCT00134056 ·Status: COMPLETED ·Phase: PHASE3

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

NCT01309672 ·Status: COMPLETED ·Phase: PHASE2

Study of ATN-224 in Patients With Prostate Cancer

NCT00405574 ·Status: UNKNOWN ·Phase: PHASE2

Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer

NCT00473746 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00471718 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

NCT03572387 ·Status: COMPLETED ·Phase: PHASE2

A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy

NCT00473512 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy

NCT00148772 ·Status: COMPLETED ·Phase: PHASE2

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

NCT05352178 ·Status: RECRUITING ·Phase: PHASE3

Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer

NCT02415621 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1

Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy

NCT01867710 ·Status: COMPLETED ·Phase: PHASE2

Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients

NCT06500741 ·Status: COMPLETED

Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer

NCT00541281 ·Status: COMPLETED ·Phase: PHASE2

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

NCT03047135 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer

NCT00502164 ·Status: COMPLETED ·Phase: PHASE1

Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer

NCT00111618 ·Status: COMPLETED ·Phase: PHASE2

Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer

NCT00104741 ·Status: COMPLETED ·Phase: PHASE3

Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT01549951 ·Status: COMPLETED ·Phase: PHASE2

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

NCT04262154 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

NCT00003516 ·Status: TERMINATED ·Phase: PHASE2

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

NCT01217697 ·Status: APPROVED_FOR_MARKETING